214697-26-4 Usage
Description
4-AMINO-5-(3-BROMOPHENYL)-7-(6-MORPHOLINO-PYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE DIHYDROCHLORIDE is a complex organic compound with a unique chemical structure. It is characterized by its pyrido[2,3-d]pyrimidine core, which is substituted with an amino group at the 4th position, a 3-bromophenyl group at the 5th position, and a 6-morpholino-pyridin-3-yl group at the 7th position. The dihydrochloride salt form of this compound enhances its solubility and stability, making it suitable for various applications in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Industry:
4-AMINO-5-(3-BROMOPHENYL)-7-(6-MORPHOLINO-PYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE DIHYDROCHLORIDE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a promising candidate for the development of new drugs targeting specific biological pathways.
Used in Research and Development:
In the field of research and development, 4-AMINO-5-(3-BROMOPHENYL)-7-(6-MORPHOLINO-PYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE DIHYDROCHLORIDE serves as a valuable tool for studying the structure-activity relationships of various biologically active molecules. Its synthesis and modification can provide insights into the design of more potent and selective drug candidates.
Used in Assay Development:
4-AMINO-5-(3-BROMOPHENYL)-7-(6-MORPHOLINO-PYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE DIHYDROCHLORIDE is employed in the development of assays for high-throughput screening of potential drug candidates. Its unique chemical properties allow for the identification of compounds with specific biological activities, such as antiviral or anticancer properties.
For example, ABT 702 Dihydrochloride is used in the assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. This application demonstrates the potential of 4-AMINO-5-(3-BROMOPHENYL)-7-(6-MORPHOLINO-PYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE DIHYDROCHLORIDE and its derivatives in the development of novel therapeutic agents for various diseases.
Biological Activity
Potent non-nucleoside adenosine kinase inhibitor (IC 50 = 1.7 nM), selective over other sites of adenosine interaction (A 1 , A 2A and A 3 receptors, adenosine transporter and adenosine deaminase). Displays oral activity in animal models of pain and inflammation.
Check Digit Verification of cas no
The CAS Registry Mumber 214697-26-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,6,9 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 214697-26:
(8*2)+(7*1)+(6*4)+(5*6)+(4*9)+(3*7)+(2*2)+(1*6)=144
144 % 10 = 4
So 214697-26-4 is a valid CAS Registry Number.
InChI:InChI=1/C22H19BrN6O.2ClH/c23-16-3-1-2-14(10-16)17-11-18(28-22-20(17)21(24)26-13-27-22)15-4-5-19(25-12-15)29-6-8-30-9-7-29;;/h1-5,10-13H,6-9H2,(H2,24,26,27,28);2*1H
214697-26-4Relevant articles and documents
5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d] pyrimidin-4-ylamine: Structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors
Matulenko, Mark A.,Lee, Chih-Hung,Jiang, Meiqun,Frey, Robin R.,Cowart, Marlon D.,Bayburt, Erol K.,DiDomenico Jr., Stanley,Gfesser, Gregory A.,Gomtsyan, Arthur,Guo, Zhu Zheng,McKie, Jeffery A.,Stewart, Andrew O.,Yu, Haixia,Kohlhaas, Kathy L.,Alexander, Karen M.,McGaraughty, Steve,Wismer, Carol T.,Mikusa, Joseph,Marsh, Kennan C.,Snyder, Ronald D.,Diehl, Marilyn S.,Kowaluk, Elizabeth A.,Jarvis, Michael F.,Bhagwat, Shripad S.
, p. 3705 - 3720 (2007/10/03)
4-Amino-5,7-disubstituted pyridopyrimidines are potent, non-nucleoside inhibitors of adenosine kinase (AK). We recently identified a potent, orally efficacious analog, 4 containing a 7-pyridylmorpholine substituted ring system as the key structural element of this template. In this report, we disclose the pharmacologic effects of five- and six-membered heterocyclic ring replacements for the pyridine ring in 4. These replacements were found to have interesting effects on in vivo efficacy and genotoxicity as well as in vitro potency. We discovered that the nitrogen in the heterocyclic ring at C(7) is important for the modulation of mutagenic side effects (Ames assay).
Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor
Lee,Jiang,Cowart,Gfesser,Perner,Ki Hwan Kim,Yu Gui Gu,Williams,Jarvis,Kowaluk,Stewart,Bhagwat
, p. 2133 - 2138 (2007/10/03)
Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC50 = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC50 = 1.7 nM) nonnucleoside AK inhibitor with oral activity in animal models of pain and inflammation.
